Background Women with infl ammatory bowel disease (IBD) are at increased risk for adverse birth outcomes such as preterm delivery and small for gestational age (SGA) infants. Most recognized cases of fetal growth restriction in singleton pregnancies have underlying placental causes. However, studies in IBD examining poor birth outcomes have focused on maternal factors. We examined whether women with IBD have a higher rate of placental infl ammation than non-IBD controls.
Introduction
Th e incidence and prevalence of infl ammatory bowel disease (IBD) is increasing worldwide [1] . Th e peak incidence of the infl ammatory bowel diseases, ulcerative colitis (UC) and Crohn's disease (CD), occurs between the ages of 15-29 [2, 3] . Th is period overlaps with the peak time for pregnancy. While disease quiescence at the time of conception is a predictor for ongoing disease inactivity during pregnancy, at least onethird of women with IBD who are in remission experience an exacerbation of their disease during pregnancy [4] . Women with active disease may be at greatest risk for poor birth outcomes. It is important to note, however, that studies have shown that even among women with quiescent IBD throughout pregnancy, the rate of adverse birth outcomes is higher compared to the general population [5] . Th us better understanding of the factors which may contribute to birth outcomes of women with IBD is needed such that targets for interventions aimed at improving neonatal well-being can be developed [5] [6] [7] [8] .
Most studies have shown an increased risk for fetal growth restriction and preterm delivery in women with IBD [5] [6] [7] [8] . Among non-IBD patients, these birth outcomes can generally be attributed to maternal, fetal, or placental factors. Maternal factors refer to a defi ciency in nutrient and oxygen delivery to the placenta whereas fetal factors relate to abnormal nutrient uptake leading to dysregulated growth. Umbilical-placental vascular anomalies, placenta previa, placental infarction, placental abruption, placental infection, and multiple gestations are categorized as placental factors. In the general population aft er excluding constitutional small for gestational age (SGA) infants, most recognized cases of fetal growth restriction in singleton pregnancies have underlying placental causes that arise from nutrient and oxygen transfer across the placenta [9] [10] [11] .
To date, studies showing an increased risk for poor birth outcomes in women with IBD have attributed their fi ndings mainly to maternal factors such as disease activity, IBD medication use, and nutritional defi ciency [12] [13] [14] . Placental factors in growth restriction among women with IBD have not been well studied. In fact, no published data is currently available examining the placental histology of these women. Th us, the purpose of this study was to compare placental histology of women with IBD to that of women without IBD. We hypothesized that there is an increased rate of placental infl ammation in women with IBD who have poor birth outcomes.
Materials and methods
We retrospectively reviewed the medical records of women with IBD enrolled in the Pregnancy in Infl ammatory Bowel Disease and Neonatal Outcomes (PIANO) registry at Women and Infants Hospital (WIH) in Providence, Rhode Island. PIANO is a prospective cohort of pregnant women at 30 IBD centers in the United States designed to determine whether medication exposure aff ects complication rates [15] . Pregnant women with IBD are prospectively enrolled and contacted every trimester, at the birth of their baby, and when the infant is 4, 9, and 12 months of age. Newborn complications and the mothers' medications along with complications of pregnancy and delivery are recorded. WIH has served as a site of enrollment since 2007. Th e study was conducted with the approval of the WIH institutional review board (IRB) and in compliance with the Health Insurance Portability and Accountability Act (HIPAA). All subjects provided informed consent prior to involvement in the study.
Subjects
Subjects enrolled in PIANO who gave birth between March 2008 and April 2011 at WIH were included in this study. A control group consisted of women without IBD or other major co-morbidities who delivered at WIH during the same time period. Th e controls, obtained from fi les of WIH Department of Pathology, were matched by gestational age to cases.
Demographic factors, medical and obstetric histories, fetal body weight, placental weight, mode of delivery, medication profi les as well as pregnancy course and birth outcomes for subjects also were documented.
IBD disease activity was assessed using a combination of clinical symptoms, labs, radiographic studies, and endoscopic fi ndings. A modifi ed version of the American College of Gastroenterology Guidelines for CD and UC was utilized to classify disease activity into one of four categories: remission, mild, moderate, or severe (Table 1 ) [16, 17] .
Placenta
Placental infl ammation is categorized by its location and type of infl ammation: acute, subacute, or chronic. Acute chorioamnionitis with or without a fetal infl ammatory response, villitis, and deciduitis are the most common types of placental infl ammation ( Table 2) .
In this study, placental and umbilical cord histology was reviewed by two, blinded perinatal pathologists for evidence of infl ammation and classifi ed according to previously published criteria (Table 2 ) [18] . A Mann-Whitney U test (GraphPad Soft ware™) was used to compare placental histology fi ndings between IBD and non-IBD mothers. Statistical signifi cance was defi ned as P<0.05.
Results
During the study period 36 subjects were enrolled in PIANO at WIH. Fourteen subjects delivered at WIH and had placental tissue available for review. Twenty-six women served as controls.
Subject demographics
Subjects ranged in age from 21 to 42 years. Th e mean age at conception was 32.4 (±4.8) years for cases. All subjects except one were Caucasian. All subjects denied smoking during pregnancy and only one subject reported alcohol use during pregnancy. Th e median gravida per subject was 1.4 (range 0-6) and median parity was 0.5 (range 0-3). Nine of the IBD mothers delivered at term (i.e., between 37-42 weeks gestation), 1 had a late preterm delivery (i.e., between 34-36 weeks), and 4 had early preterm deliveries (i.e., before 34 weeks). Fift een of the non-IBD mothers delivered at term, 4 had late preterm deliveries, and 7 had early preterm deliveries. Among women with IBD, the distribution of the disease subtype was as follows: 7 (50%) had UC, 5 (36%) had CD, and 2 (14%) had IBD-unclassifi ed (IBD-U). Demographic and disease data for cases is summarized in Table 3 .
Disease activity and medication use
Five subjects had a moderate exacerbation of their disease during pregnancy while one had a mild exacerbation ( Table 3) . Four of the fi ve subjects with moderate exacerbation of disease were placed on corticosteroids. One subject diagnosed with de novo CD in the third trimester also was treated with corticosteroids and metronidazole. Nine subjects were treated with oral or topical mesalamine. Th e 2 subjects treated with an immunomodulator (i.e., azathioprine or 6-mercaptopurine) and 2 of the 3 treated with a tumor necrosis factor (TNF)-α inhibitor were started on their medication prior to pregnancy. One subject was changed from adalimumab to certolizumab at 30 weeks gestation and another subject discontinued her infl iximab at 30 weeks gestation. One subject was started on certolizumab pegol during her pregnancy due to a moderate disease fl are. At the time of conception, all IBD patients were clinically asymptomatic though four were corticosteroid dependent. Two subjects took no medications for their IBD during the course of their pregnancy.
Summary of outcomes
All IBD and non-IBD subjects had singleton pregnancies that resulted in live births. Th ere were no congenital anomalies. Eight (57%) of the IBD mothers underwent Cesarean sections. Two IBD patients had pregnancies complicated by preeclampsia and 4 developed gestational diabetes.
Among the 26 non-IBD subjects, eleven (42%) pregnancies resulted in preterm deliveries, fi ve (19%) had SGA births, and two (8%) had large for gestational age births as it is used only once births.
Placental weight and histology
Twelve of fourteen cases (86%) had SGA placentas defi ned as placental weights below the 10th percentile aft er accounting for gestational age (Table 4) [19, 20] . Th e fetal to placental weight ratios for cases however fell within the expected range [19, 20] .
Acute chorioamnionitis (ACA) was found in 1 of 14 placentas (7%) from subjects with IBD compared to 27% of the control placentas (P=0.32). Th e IBD patient with ACA had a moderate fl are during her pregnancy requiring corticosteroids and remained corticosteroid-dependent with resolved symptoms at conception. Th e IBD placenta with ACA also had funisitis suggestive of a fetal infl ammatory response to ACA in one of the umbilical arteries. Only one of the seven non-IBD placentas with ACA had umbilical cord arteritis. No clinically signifi cant cases of placental villitis or deciduitis were observed in either group. Other than vasculitis in the case with ACA and one of the controls with ACA, no other subjects had evidence of umbilical cord abnormalities. Th e concordance rate between the two blinded pathologists was 100%.
Discussion
Pregnant women with IBD, irrespective of medical treatment or in some cases disease activity, are at increased risk for such adverse birth outcomes as spontaneous abortion, low birth weight and SGA. infants, and preterm delivery [5] [6] [7] 14] . Placental histological fi ndings such as chronic villitis and deciduitis and ACA repeatedly have been associated with preterm birth, spontaneous abortion, and intrauterine growth retardation [21] [22] [23] [24] . Prior studies have documented a signifi cant increase in placental pathology in a variety of immune-mediated diseases including autoimmune thyroid disease, idiopathic thrombocytopenic purpura, and multiple sclerosis [25, 26] . Prior to this study placental histology had not been examined to determine its association with poor birth outcomes in women with IBD. Our results indicate that placental pathology may not be increased in these patients. In fact, our data suggest chorioamnionitis may occur less frequently in placentas of women with IBD compared to women without IBD.
Placental infl ammatory lesions aff ect the chorion, amniotic fl uid, decidua, placental villi, and fetal vessels ( Table 2) . ACA is a major cause of spontaneous preterm birth and histologically it is defi ned by presence of acute infl ammatory cell infi ltration within placental chorioamnion and umbilical cord. Th e maternal infl ammatory response precedes the fetal response and it is characterized by infi ltration of chorionic plate and placental membranes by maternal neutrophils [21] . Transmigration of neutrophils from umbilical cord or chorionic vessels represents fetal infl ammatory response and this can go through a series of quantifi able stages. Hematogenous infections usually give rise to acute villitis, characterized by neutrophilic infi ltration of villous stroma, capillaries and intervillous space. Chronic villitis is defi ned as presence of chronic infl ammatory cells infi ltrating the terminal villous stroma. Th e etiology of chronic villitis is still unknown, but it is thought to be immune mediated. It can be seen in association with chronic deciduitis, which is diagnosed when chronic infl ammatory infi ltrate in decidua basalis is identifi ed. Chronic deciduitis is usually associated with genital tract infections.
ACA, a clinical or histological diagnosis commonly occurring aft er prolonged premature rupture of membrane, is typically due to a polymicrobial infection secondary to ascending bacteria from the genitourinary tract, gastrointestinal (GI) tract, skin, or oral cavity. Ureaplasma urealyticum and Gardnerella vaginalis are the 2 most commonly cultured organisms from placentas of women with ACA [27] . Since the composition of the microbial environment in the gut diff ers in individuals with IBD compared with those without IBD [28] [29] [30] , translocation of bacteria from the GI tract to the urovaginal tract may result in a diff erent bacterial milieu. Even in the setting of immunosuppression this bacterial composition may make IBD mothers less susceptible to ACA. In addition to microbial factors, certain genetic factors may increase the risk of ACA. For example, specifi c TNF-α genes may make individuals genetically susceptible to chorioamnionitis and therefore inhibition of this cytokine could decrease the probability of ACA [31] . Th ree of the 14 IBD patients in this study were on anti-TNF agents which may have protected them from ACA.
Small placental size and fetal body weight to placental ratio has been associated with fetal growth impairment [32] . In this study, 86% of the cases met the criteria for SGA placentas. Placental weight also has been evaluated in other autoimmune diseases like systemic lupus erythematosus where renal involvement is associated with a lower mean placental weight [33] . Th e effi ciency of placenta to transfer nutrients to the fetus is an important determinant of fetal size and can be measured indirectly as fetal body weight to placental weight ratio. Despite a high prevalence of SGA placentas, fetal body weight to placenta ratio among cases fell within a normal range suggesting there may be increased IBD placental effi ciency. Th is is consistent with studies showing that in normoxic conditions before term, lighter placentas have higher effi ciency than heavier placentas due to the fetal drive to obtain nutrients [34] .
One strength of this study is that two blinded pathologists reviewed all placentas. Interobserver variability of placental histopathologic diagnosis has been found to be good to excellent. In one study of two pathologists examining 250 placentas for infl ammatory lesions including ACA and villitis, the kappa values ranged from 0.70-0.83 [35] . Th e concordance rate in our study of 40 placentas was 100%. Other studies examining a similar number placentas found lower percentage agreement rates for chronic deciduitis (76%) and kappa value for ACA (0.83) [36, 37] . However, these studies involved at least fi ve pathologists and more frequent placental lesions compared to our study.
Despite the lack of placental infl ammation, the SGA and preterm delivery rate of the IBD subjects in our study (21% and 36%, respectively) were higher than those that have been previously reported. In a population-based cohort from Washington state, Dominitz et al found that women with CD when compared to non-IBD controls had a preterm delivery rate of 15.2% (vs. 7.2% in non-IBD controls), LBW delivery rate of 16.8% (vs. 5.3%), and a SGA rate of 15.2% (vs. 6.9%) [6] . Similarly, using a population-based cohort of pregnant women with IBD in northern California, Mahadevan et al found that women with IBD regardless of disease activity had a pre-term delivery rate of 14.2% (vs. 9.6% for controls) and SGA rate of 12% (vs. 10% for controls) [5] . Several factors may have contributed to the diff erences in SGA and preterm rates in our cohort compared to prior studies. First, advanced maternal age is a known risk factor preterm and SGA infants. In our IBD cohort, the mean age of women at conception was 32.4 which is higher than the mean age for the women in the previously cited studies [5, 6] . In addition, disease activity may have been greater in our subjects. Only the study by Mahadevan et al took into account disease activity when evaluating pregnancy outcomes. In that cohort of pregnant women immunosuppressants were used by only 4% and corticosteroids were used by 21% [5] . In comparison, in our study 36% of patients were on immunomodulators and/or an anti-TNF-α agent and 36% were on an oral corticosteroid during their pregnancy. Th is suggests that baseline disease severity and disease activity during pregnancy may have been greater in our population. Because WIH is one of the nation's leading specialty hospitals for women and newborns and serves as a referral center for high-risk pregnancies, selection bias may have contributed to the higher SGA and preterm delivery rates seen in our study.
Inadequate maternal nutrition and active disease consistently have been associated with poor birth outcomes in women with IBD [12, 38, 39] . Medications used in IBD also have been implicated [13, 14] . However, with the exception of methotrexate, the medications typically used to treat IBD such as 5-amionsalicylates, corticosteroids, immunomodulators, and anti-TNF-α agents generally have been deemed compatible for use during pregnancy [15, 40] . Other maternal factors linked with adverse birth outcomes in women with IBD include smoking and high circulating prostaglandin levels [12, 14, 41] .
In this study the rate of placental pathology defi ned as villitis, deciduitis, and chorioamnionitis was not higher in an IBD cohort compared to gestational-age matched non-IBD controls. Th e low rate of infl ammatory lesions may be attributable to selection bias since all cases were enrolled in the PIANO registry and were being closely monitored by a team of gastroenterologists, obstetricians, and perinatologists and had their disease aggressively controlled. Nevertheless, although few infl ammatory lesions were identifi ed, the preterm birth and SGA rates were elevated in our cohort compared to rates in the literature suggesting disease severity and disease activity may have been higher in our population compared to the general pregnant IBD population.
Th e sample size in this study does not allow for defi nitive conclusions. However, our analysis suggests limited placental pathology in pregnant women with IBD. Rates of preterm delivery and SGA, however, were higher than what has been reported in the literature. Further studies are necessary to examine placental pathology as a cause of adverse birth outcomes in women with IBD.
Summary Box
What is already known:
• Women with infl ammatory bowel disease (IBD) are at increased risk for poor birth outcomes • Most cases of fetal growth restriction in singleton pregnancies have underlying placental causes • Studies in pregnancy and IBD have focused on maternal factors to explain poor birth outcomes
What the new fi ndings are:
• Placental infl ammation does not appear to be responsible for poor birth outcomes in IBD • Chorioamnionitis may occur less frequently in placentas of women with IBD • Further studies are necessary to examine the role of placental infl ammation in poor birth outcomes in IBD
